CHRM1

Muscarinic acetylcholine receptor M1 · P11229 · CHRM1 on Sugi Atlas →

677,768 patent compounds predicted against CHRM1, 421,735 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dimethindene (SCHEMBL18759)	1.00	20/20
Clozapine (SCHEMBL8397)	1.00	9/20
Carbamoylcholine (SCHEMBL2792)	1.00	8/20
Acetylcholine (SCHEMBL3216)	1.00	8/20
Mizolastine (SCHEMBL5061)	1.00	8/20
Cyclandelate (SCHEMBL5123)	0.54	7/20
Oxotremorine (SCHEMBL2128)	1.00	6/20
Carbamoylcholine (SCHEMBL2791)	1.00	6/20
Oxybutynin (SCHEMBL2992)	1.00	6/20
Ipratropium (SCHEMBL3124)	1.00	6/20
Ipratropium (SCHEMBL3125)	1.00	6/20
Dicyclomine (SCHEMBL3317)	1.00	6/20
Promethazine (SCHEMBL4700)	1.00	6/20
Amitriptyline (SCHEMBL7824)	1.00	6/20
Methylpromazine (SCHEMBL18993)	1.00	6/20
Methylpromazine (SCHEMBL18994)	1.00	6/20
Tiotropium (SCHEMBL4589)	0.98	6/20
Tiotropium (SCHEMBL8625)	0.98	6/20
Hydrochloric Acid (SCHEMBL15954)	0.65	6/20
Carbinoxamine (SCHEMBL5070)	0.62	6/20

Clinical trials — most relevant to CHRM1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD	PHASE4	COMPLETED
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia	PHASE4	COMPLETED
Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause	PHASE4	COMPLETED
Galantamine for Cognition in People With Schizophrenia	PHASE4	COMPLETED
Metoclopramide as Treatment of Clozapine-induced Hypersalivation	PHASE3	COMPLETED
Galantamine for Cognitive Deficits in Schizophrenia	PHASE2/PHASE3	COMPLETED
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease	PHASE1/PHASE2	RECRUITING
A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma	PHASE2	COMPLETED
Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response	PHASE2	COMPLETED
Nicotinic Receptors and Schizophrenia	PHASE1/PHASE2	WITHDRAWN
Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI	PHASE2	COMPLETED
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants	PHASE1	NOT_YET_RECRUITING
M1 Schizophrenia PET Study	PHASE1	COMPLETED
Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants	PHASE1	COMPLETED
PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers	PHASE1	COMPLETED
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care	PHASE1	COMPLETED
PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor	PHASE1	WITHDRAWN
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing	PHASE1	COMPLETED
Putative Cognitive Enhancer VU319	PHASE1	COMPLETED
Toward a Computationally-Informed, Personalized Treatment for Hallucinations	EARLY_PHASE1	RECRUITING
Cholinergic Mechanisms of Attention in Aging	EARLY_PHASE1	COMPLETED
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy	nan	COMPLETED
Penehyclidine for Prevention of Nausea and Vomiting After Bimaxillary Surgery	nan	COMPLETED
Mental Ability Challenge Study in Adults With and Without HIV	nan	COMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine	nan	WITHDRAWN
Penehyclidine and Postoperative Nausea and Vomiting After Bimaxillary Surgery	nan	COMPLETED
Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers	nan	UNKNOWN
Cholinergic Status and the Metabolic Syndrome	nan	UNKNOWN
Cholinergic Receptor Imaging in Dystonia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CHRM1 binder may also engage these)

Protein	Name	Similarity
P56489	—	1.000	P56489 →
P04761	—	1.000	P04761 →
Q5R949	—	1.000	Q5R949 →
P12657	—	1.000	P12657 →
P08482	—	1.000	P08482 →
P56490	—	0.981	P56490 →
CHRM5	Muscarinic acetylcholine receptor M5	0.980	landscape →
Q5IS98	—	0.979	Q5IS98 →
Q5IS53	—	0.978	Q5IS53 →
P08911	—	0.976	P08911 →
Q920H4	—	0.976	Q920H4 →
P11617	—	0.974	P11617 →
Q60613	—	0.974	Q60613 →
P48974	—	0.972	P48974 →
Q9WU02	—	0.972	Q9WU02 →
P32211	—	0.971	P32211 →
P08485	—	0.971	P08485 →
Q6TLI7	—	0.969	Q6TLI7 →
P70174	—	0.968	P70174 →
P30543	—	0.968	P30543 →
AVPR1B	Vasopressin V1b receptor	0.968	landscape →
Q9N2A4	—	0.968	Q9N2A4 →
P46616	—	0.966	P46616 →
Q5YKK9	—	0.966	Q5YKK9 →
ADORA2A	Adenosine receptor A2a	0.966	landscape →
P17200	—	0.966	P17200 →
Q28838	—	0.966	Q28838 →
CHRM4	Muscarinic acetylcholine receptor M4	0.964	landscape →
Q95JG1	—	0.964	Q95JG1 →
Q5IS72	—	0.964	Q5IS72 →